Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Scutelnic, A; van, de, Munckhof, A; Krzywicka, K; van, Kammen, MS; Lindgren, E; Cordonnier, C; Kleinig, TJ; Field, TS; Poli, S; Lemmens, R; Middeldorp, S; Aaron, S; Borhani-Haghighi, A; Arauz, A; Kremer, Hovinga, JA; Günther, A; Putaala, J; Wasay, M; Conforto, AB; de, Sousa, DA; Jood, K; Tatlisumak, T; Ferro, JM; Coutinho, JM; Arnold, M; Heldner, MR; Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group.
Sex differences in cerebral venous sinus thrombosis after adenoviral vaccination against COVID-19.
Eur Stroke J. 2023; 8(4): 1001-1010. Doi: 10.1177/23969873231185213 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Study Group Members Med Uni Graz:: Gattringer Thomas
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: INTRODUCTION: Cerebral venous sinus thrombosis associated with vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) is a severe disease with high mortality. There are few data on sex differences in CVST-VITT. The aim of our study was to investigate the differences in presentation, treatment, clinical course, complications, and outcome of CVST-VITT between women and men. PATIENTS AND METHODS: We used data from an ongoing international registry on CVST-VITT. VITT was diagnosed according to the Pavord criteria. We compared the characteristics of CVST-VITT in women and men. RESULTS: Of 133 patients with possible, probable, or definite CVST-VITT, 102 (77%) were women. Women were slightly younger [median age 42 (IQR 28-54) vs 45 (28-56)], presented more often with coma (26% vs 10%) and had a lower platelet count at presentation [median (IQR) 50x10⁹/L (28-79) vs 68 (30-125)] than men. The nadir platelet count was lower in women [median (IQR) 34 (19-62) vs 53 (20-92)]. More women received endovascular treatment than men (15% vs 6%). Rates of treatment with intravenous immunoglobulins were similar (63% vs 66%), as were new venous thromboembolic events (14% vs 14%) and major bleeding complications (30% vs 20%). Rates of good functional outcome (modified Rankin Scale 0-2, 42% vs 45%) and in-hospital death (39% vs 41%) did not differ. DISCUSSION AND CONCLUSIONS: Three quarters of CVST-VITT patients in this study were women. Women were more severely affected at presentation, but clinical course and outcome did not differ between women and men. VITT-specific treatments were overall similar, but more women received endovascular treatment.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Female - administration & dosage; Male - administration & dosage; Adult - administration & dosage; COVID-19 - administration & dosage; Sex Characteristics - administration & dosage; Hospital Mortality - administration & dosage; Purpura, Thrombocytopenic, Idiopathic - administration & dosage; Thrombocytopenia - administration & dosage; Venous Thromboembolism - administration & dosage; Sinus Thrombosis, Intracranial - epidemiology; Disease Progression - administration & dosage; Vaccination - administration & dosage
Find related publications in this database (Keywords): VITT; CVST; sex differences